8 minutes | Feb 8, 2021

Preliminary Data on Johnson and Johnson Vaccine

A randomized, multicenter, double-blind, placebo-controlled, phase 1/2a clinical trial to evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S - a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein
Play
Like
Play Next
Mark
Played
Share